Frequently asked / answered from the record
CJC-1295 questions, answered from the published research
The queries people actually type about CJC-1295, each answered directly and cited to the literature where the answer is quantitative. Where the evidence is thin, the answer says so.
Frequently asked questions about CJC-1295
Direct answers to the most common CJC-1295 questions, drawn from the published research and pointing to the studies behind each number. Where a controlled answer does not exist, this page says so plainly rather than filling the gap.
What does CJC-1295 do?
It is a long-acting GHRH analog that binds the pituitary GHRH receptor to stimulate growth-hormone release, which in turn raises IGF-1 [6]. In healthy adults, single doses elevated GH and IGF-1 for days, with the half-life estimated at 5.8 to 8.1 days [1]. It moves biomarkers in research participants; it is not an approved therapy.
What is CJC-1295?
A synthetic analog of growth-hormone-releasing hormone built on hGRF(1-29) with four protease-resistant substitutions; the DAC variant adds covalent serum-albumin binding for a multi-day half-life [6]. The no-DAC form keeps the substitutions but lacks the albumin linker and is short-acting.
What does the published human research on CJC-1295 actually show?
Early Phase-1 pharmacokinetic studies in healthy adults established dose-dependent, multi-day GH and IGF-1 elevation with a 5.8-8.1 day half-life [1] and preserved pulsatility [2]. There are no large efficacy or long-term safety trials [1]; the human evidence base is small, old, and short-term.
What to expect when taking CJC-1295?
In the published human pharmacokinetic studies, the measured outcome was sustained, dose-dependent elevation of GH and IGF-1 over days [1]. These describe biomarker responses in research participants, not promised personal results; CJC-1295 is unapproved and no outcome trial exists.
Is CJC-1295 a steroid?
No. It is a peptide GHRH analog that acts on the GHRH receptor to stimulate the body's own growth-hormone release [6]. It is not an anabolic-androgenic steroid and is not exogenous growth hormone; it works upstream, by signaling the pituitary rather than supplying a hormone directly.
Is CJC-1295 safe?
CJC-1295 is unapproved and human safety data are limited to short early trials. Theoretical concerns include fluid retention, effects on insulin sensitivity, and the IGF-1/cancer epidemiology [4], and FDA briefing materials for the 2024 compounding advisory committee flagged immunogenicity [1]. No long-term safety trial exists.
Are CJC-1295 peptides safe?
Human safety evidence is thin and short-term. Reported and theoretical concerns from GH-axis stimulation include fluid retention and edema, effects on insulin sensitivity, the IGF-1/cancer epidemiology [4], and immunogenicity flagged in FDA briefing materials [1]. The published studies were not designed to assess long-term safety.
What are the side effects of CJC-1295?
From GH-axis stimulation generally, studies and reviews describe fluid retention and edema driven by GH-related sodium reabsorption, possible effects on insulin sensitivity, and theoretical IGF-1-related concerns [4]. Controlled long-term safety data for CJC-1295 itself are lacking [1], so most side-effect information is extrapolated from the GH class.
Is CJC-1295 FDA approved?
No. CJC-1295 is not approved by the FDA or any major regulator for human use; it is handled as an unapproved research chemical [1]. Its safety was reviewed by the FDA's 2024 Pharmacy Compounding Advisory Committee, where immunogenicity and other concerns for GH secretagogues including CJC-1295 were cited [1].
How much CJC-1295 should I take?
There is no approved human dose. Published research used single subcutaneous doses of 30, 60 or 90 micrograms per kilogram in pharmacokinetic studies [1] [2]; community protocols of 100-300 micrograms are not derived from controlled human trials [1]. This site reports the research record, not a dosing recommendation.
How much CJC-1295 DAC should I take?
No validated human dose exists for the DAC variant. Its multi-day half-life of 5.8 to 8.1 days means it was studied with infrequent dosing in pharmacokinetic work [1], and once-daily dosing fully normalized growth in GHRH-knockout mice [7]. These describe research administration, not a human protocol.
What is CJC-1295 with DAC?
The Drug Affinity Complex variant carries a maleimide linker that covalently binds circulating serum albumin via Cys34, extending the plasma half-life toward that of albumin and giving a multi-day duration of action [6]. The effective circulating species is a large peptide-albumin complex of roughly 66 kilodaltons.
What is CJC-1295 DAC?
CJC-1295 DAC is the albumin-conjugating, long-acting form of the tetrasubstituted GHRH(1-29) analog. In rats it gave a 4-fold GH area-under-the-curve over the unconjugated peptide and was detectable beyond 72 hours [6]. In humans its half-life is 5.8 to 8.1 days [1].
What is CJC-1295 ipamorelin?
It refers to combining the GHRH analog CJC-1295 with ipamorelin, a selective GH secretagogue acting on the ghrelin/GHS receptor. The two act through different receptors and were studied as a synergistic GH-releasing pair in the broader literature [11], though no controlled combination trial in healthy adults exists.
How to reconstitute CJC-1295?
It ships lyophilized and is reconstituted with bacteriostatic water and refrigerated in research handling [6]; oral bioavailability is negligible, so subcutaneous injection is the route studied [6]. This describes research handling as the literature reports it, not a preparation instruction for human use.
Where to inject CJC-1295?
The published pharmacokinetic studies used subcutaneous administration; early GRF(1-29) work also used the intravenous route [1]. This describes the research route only. The literature characterizes how the compound was administered in studies, not a site-of-injection instruction for personal use.
How does CJC-1295 affect IGF-1 levels?
By driving pituitary GH release, CJC-1295 raises hepatic IGF-1. Single 30-60 microgram-per-kilogram doses produced 1.5- to 3-fold IGF-1 increases lasting nine to eleven days, with IGF-1 above baseline up to 28 days after multiple doses [1]. The effect tracks the GH/IGF-1 axis it stimulates.
Does CJC-1295 and ipamorelin work?
GHRH analogs and GHRPs act through distinct receptors and synergize, producing GH release greater than either alone [11]. The ipamorelin pairing rests on that two-pathway rationale rather than on controlled CJC-1295/ipamorelin trials, which the published literature does not contain.
How much CJC-1295 / ipamorelin should I take?
No combination has an established human dose. The pairing is grounded in the GHRH-plus-GHRP synergy rationale [11], but published controlled dosing data for the CJC-1295/ipamorelin combination in healthy adults do not exist [1]. Any circulating protocol is extrapolation, not trial-derived guidance.
Does CJC affect testosterone?
CJC-1295 acts on the GH/IGF-1 axis, not the gonadal axis. The published CJC-1295 literature does not establish a direct testosterone effect; GH-secretagogue studies in hypogonadal men measured IGF-1 rather than testosterone changes [9], so a testosterone effect is not documented in the record.
Does CJC-1295 affect testosterone?
The published CJC-1295 research does not document a testosterone effect. CJC-1295 acts on the GHRH receptor and the GH/IGF-1 axis [6] rather than directly on the hypothalamic-pituitary-gonadal axis, and the secretagogue studies in this area measured IGF-1 as the endpoint [9].
Does CJC-1295 lower testosterone?
The published CJC-1295 research does not document a testosterone-lowering effect. CJC-1295 acts on the GHRH receptor and the GH/IGF-1 axis [6] rather than directly on the hypothalamic-pituitary-gonadal axis, so no lowering of testosterone is established in the cited literature.
Are peptides safer than TRT?
This cannot be answered from the CJC-1295 literature. CJC-1295 is an unapproved GHRH analog with limited human data [1], and no head-to-head safety comparison with testosterone-replacement therapy exists in the cited research. A safety ranking between the two is not supported by the published evidence.